Bin Liu, PhD

Title(s)Professor, Anesthesia
SchoolSchool of Medicine
Address1001 Potrero Ave, #163
San Francisco CA 94110
Phone628-206-3251
ORCID ORCID Icon0000-0002-5836-2333 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Princeton University, Princeton, NJB.A.1990Molecular Biology
    University of California, San FranciscoPh.D.1994Biochemistry & Biophysics

    Collapse Overview 

    Collapse Research 
    Collapse Research Activities and Funding
    Bispecific T cell engager targeting a highly specific tumor cell surface antigen
    NIH R01CA286428Jun 1, 2024 - May 31, 2029
    Role: Principal Investigator
    Bispecific antibody-drug conjugates against emerging targets in metastatic lethal prostate cancer
    DOD HT9425-24-1-0341Apr 15, 2024 - Mar 31, 2027
    Role: Principal Investigator
    Develop novel bispecific antibody-drug conjugates against metastatic lethal prostate cancer across subtype
    NIH R01CA289874Apr 1, 2024 - Mar 31, 2029
    Role: Principal Investigator
    Combination antigen sensing engineered T cell for precise recognition and enhanced elimination of solid tumors
    NIH R01CA280440Apr 1, 2023 - Mar 31, 2028
    Role: Co-Principal Investigator (MPI)
    Novel radioimmunoconjugates for targeted alpha-particle therapy of metastatic prostatic cancer
    NIH R01CA223767Jun 1, 2018 - May 31, 2023
    Role: Co-Principal Investigator (MPI)
    Internalizing human antibody-targeted nanosized siRNA therapeutics
    NIH R01CA171315Aug 6, 2012 - Jul 31, 2019
    Role: Principal Investigator
    Identifying antigens bound by novel scFvs targeting all subtypes of mesothelioma
    NIH R01CA129491Mar 1, 2010 - Dec 31, 2015
    Role: Principal Investigator
    Selection of internalizing human antibodies targeting pancreatic tumor cells in s
    NIH R21CA137429Feb 1, 2009 - Jan 31, 2012
    Role: Principal Investigator
    Internalizing antibody-targeted nanosized siRNA therapeutics
    NIH R21CA135586Dec 5, 2008 - Nov 30, 2011
    Role: Principal Investigator
    Mapping a clinically significant internalizing tumor epitope space
    NIH R01CA118919Mar 7, 2006 - Mar 31, 2016
    Role: Principal Investigator
    Tumor specific cell sruface epitope- molecular evolution
    NIH R21DK066429Feb 1, 2004 - Jan 31, 2007
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Academic Senate

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Development of CD46 Targeted Alpha Theranostics in Prostate Cancer using134Ce/225Ac-Macropa-PEG4-YS5. Theranostics. 2024; 4(14):1344-1360. Kondapa Naidu Bobba, Anil P. Bidkar, Anju Wadhwa, Niranjan Meher, Suchi Drona, Alexandre M. Sorlin, Scott Bidlingmaier, Li Zhang, David M. Wilson, Emily Chan, Nancy Y. Greenland, Rahul Aggarwal, Henry F. VanBrocklin, Jiang He, Jonathan Chou, Youngho Seo, Bin Liu, Robert R. Flavell.
    2. A phase 1b dose escalation study of FOR46, a novel antibody-drug conjugate targeting a tumor-specific epitope of CD46, in combination with enzalutamide (Enza) in patients with metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 2024; 16s(42):5066. Nonna Shakhnazaryan, Nathan Curry, Medini Rastogi, Daniel Avins, Shrina Pandey, Ivan de Kouchkovsky, Daniel Kwon, Arpita Desai, Kelly N. Fitzgerald, Rohit Bose, Jonathan Chou, Terence W. Friedlander, Vadim S Koshkin, Lawrence Fong, Maya Aslam, Khadija Siddiqua, Eric J. Small, Bin Liu, Robert R. Flavell, Rahul Raj Aggarwal.
    3. CD46-targeted theranostics for Positron Emission Tomography and 225Ac-radiopharmaceutical Therapy of Multiple Myeloma. Clin Cancer Res. 2023; PMCID: PMC10905524. Anju Wadhwa, Sinan Wang, Bonell Patino Escobar, Anil P. Bidkar, Kondapa Naidu Bobba, Emily Chan, Niranjan Meher, Scott Bidlingmaier, Yang Su, Suchi Drona, Huimin Geng, Vishesh Sarin, Henry F. VanBrocklin, David M. Wilson, Jiang He, Li Zhang, Veronica Steri, Sandy Wong, Tom Martin, Youngho Seo, Bin Liu, Arun P. Wiita, Robert R. Flavell. 2023 Dec 18. PMID: 38109209 PMCID: PMC10905524. doi: 10.1158/1078-0432.CCR-23-2130.
    4. CD46-ADC Reduces the Engraftment of Multiple Myeloma Patient-Derived Xenografts. Cancers. 2023; 22(15):5335. Michael J. VanWyngarden, Zachary J. Walker, Yang Su, Olivia Perez de Acha, Brett M. Stevens, Peter A. Forsberg, Tomer M. Mark, William Matsui, Bin Liu*, Daniel W. Sherbenou*. (*co-senior authors).
    5. CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment. J Exp. Clin. Cancer Res. 2023; 1(42):61. Jun Li, Tao Huang, Jun Hua, Qiong Wang, Yang Su, Ping Chen, Scott Bidlingmaier, Allan Li, Zhongqiu Xie, Anil Bidkar, Sui Shen, Weibin Shi, Youngho Seo, Robert R. Flavell, Daniel Gioeli, Robert Dreicer, Hui Li, Bin Liu*, Jiang He*. (*co-senior authors).
    6. Evaluation of 134Ce/134La as a PET Imaging Theranostic Pair for 225 Ac a-Radiotherapeutics. J Nucl Med. 2023; 7(64):1076-1082. Kondapa Naidu Bobba, Anil P Bidkar, Niranjan Meher, Cyril Fong, Anju Wadhwa, Suchi Dhrona, Alex Sorlin, Scott Bidlingmaier, Becka Shuere, Jiang He, David M. Wilson, Bin Liu, Youngho Seo, Henry F. VanBrocklin, Robert R. Flavell.
    7. Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 2022; 16(40):s3001. Aggarwal, R.R., Vuky, J., VanderWeele, D.J., Rettig, M., Heath, E.I., Beer, T.M., Huang, J., Pawlowska, N., Sinit, R., Abbey, J., Liu, B., Nasoff, M., Dorr, A., Small, E.J.
    8. Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 2022; (40):16_s3001. Aggarwal, R.R., Vuky, J., VanderWeele, D.J., Rettig, M., Heath, E.I., Beer, T.M., Huang, J., Pawlowska, N., Sinit, R., Abbey, J., Liu, B., Nasoff, M., Dorr, A., Small, E.J.
    9. Modular Design of Synthetic Receptors for Programmed Gene Regulation in Cell Therapies. Cell. 2022; 8(185):1431-1443. Zhu, I., Liu, R., Garcia, J.M., Hyrenius-Wittsten, A., Piraner, D., Alavi, J., Israni, D.V., Liu, B., Khalil, A.S., Roybal, K.T.
    10. Enhanced Solid Tumor Recognition and T cell Stemness with SynNotch CAR Circuits. Science Translational Medicine. 2021; 591(13):eabd8836. Hyrenius-Wittsten, A., Su, Y., Park, M., Garcia, J.M., Perry, N., Montgomery, G., Liu, B*., Roybal, K.T*.
    11. A first-in-human study of FOR46 in men with metastatic castration resistant prostate cancer (mCRPC). Annals of Oncology. 2021; 32:S5, S639. R.R. Aggarwal, J. Vuky, D. VanderWeele, M. Rettig, E. Heath, M. Nasoff, A. Dorr, B. Liu, E.J. Small.
    12. Molecular imaging of prostate cancer targeting CD46 using immunoPET. Clinical Cancer Res. 2020; 5(27):1305-1315. Wang, S., Li, J., Hua, J., Su, Y., Beckford-Vera, D., Zhao, W., Jayaraman, M., Huynh, T.L., Zhao, N., Wang, Y.H., Huang, Y., Qin, F., Shen, S., Gioeli, D., Dreicer, R., Sriram, R., Egusa, E.A., Chou, J., Feng, F., Aggarwal, R., Evans, M.J., Seo, Y., Liu, B.*, Flavell, R.R.*, He, J.* .
    13. Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma. Clinical Cancer Res. 2020; 22(26):6028-6038. Sherbenou, D.W., Su, Y., Behrens, C.R., Aftab, B.T., Perez de Acha, O., Murnane, M., Bearrows, S.C., Hann, B.C., Wolf, J.L., Martin, T.G., and Liu, B.
    14. ALPPL2 is a highly specific and targetable tumor cell surface antigen. Cancer Res. 2020; 20(80):4552-4564. Su, Y., Zhang, X., Bidlingmaier, S., Behrens, C.R., Lee, N.K., and Liu, B.
    15. Quantitative (99m)Tc Labeling Kit for HYNIC-Conjugated Single Chain Antibody Fragments Targeting Malignant Mesothelioma. Bioconjug Chem. 2020; 7(31):1750-1755. He, J., Feng, J., Su, Y., Seo, Y., and Liu, B.
    16. LegoBody: facile generation of bispecific and multi-specific antibodies. BioRxiv. 2020. Lang, S., Yang, S., Bidlingmaier, S., Lee, N-K., Liu, B. View Publication.
    17. Manipulation of cell-type selective antibody internalization by a guide-effector bispecific design. Mol Cancer Ther. 2019; 6(18):1092-1103. Lee, N.K., Su, Y., Bidlingmaier, S., and Liu, B.
    18. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight. 2018; 17(3):e121497. Su, Y., Liu, Y., Behrens, C.R., Bidlingmaier, S., Lee, N.K., Aggarwal, R., Sherbenou, D.W., Burlingame, A.L., Hann, B.C., Simko, J.P., Premasekharan, G., Paris, P.L., Shuman, M.A., Seo, Y., Small, E.J., and Liu, B.
    19. Cell-type specific potent Wnt signaling blockade by bispecific antibody. Sci Rep. 2018; 1(8):766. Lee, N.K., Zhang, Y., Su, Y., Bidlingmaier, S., Sherbenou, D.W., Ha, K.D., Liu, B.
    20. Modular Construction of Large Non-Immune Human Antibody Phage-Display Libraries from Variable Heavy and Light Chain Gene Cassettes. Methods Mol Biol. 2018; (1701):61-82. Lee, N.K., Bidlingmaier, S., Su, Y., Liu, B.
    21. Combine Phage Antibody Display Library Selection on Patient Tissue Specimens with Laser Capture Microdissection to Identify Novel Human Antibodies Targeting Clinically Relevant Tumor Antigens. Methods Mol Biol. 2018; (1701):331-347. Su, Y., Bidlingmaier, S., Lee, N.K., Liu, B.
    22. Identification of Novel Macropinocytosing Human Antibodies by Phage Display and High-Content Analysis. Methods Enzymol. 2017; (585):91-110. Ha, K., Bidlingmaier, S., Su, Y., Lee, N.K., Liu, B.
    23. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. J Clin Invest. 2016; 12(126):4640-4653. Sherbenou, D.W., Aftab, B.T., Su, Y., Behrens, C.R., Wiita, A., Logan, A.C., Acosta-Alvear, D., Hann, B.C., Walter, P., Shuman, M.A., Wu, X., Atkinson, J.P., Wolf, J.L., Martin, T.G., Liu, B.
    24. Proteome-wide identification of novel ceramide-binding proteins by yeast surface cDNA display and deep sequencing. Mol Cell Proteomics. 2016; 4(15):1232-45. Bidlingmaier, S., Ha, K., Lee, N.K., Su, Y., Liu, B.
    25. Macropinocytosis exploitation by cancers and cancer therapy. Frontier Physiology. 2016; (7):381. Ha, K., Bidlingmaier, S., Su, Y., Lee, N.K., Liu, B.
    26. Identification of novel protein-ligand interactions by exon microarray analysis of yeast surface displayed cDNA library selection outputs. Methods Mol Biol. 2015; (1319):179-92. Bidlingmaier, S., Liu, B.
    27. Combining phage and yeast cell surface antibody display to identify novel cell type-selective internalizing human monoclonal antibodies. Methods Mol Biol. 2015; (1319):51-63. Bidlingmaier, S., Liu, B.
    28. Utilizing Yeast Surface Human Proteome Display Libraries to Identify Small Molecule-Protein Interactions. Methods Mol Biol. 2015; (1319):203-14. Bidlingmaier, S. and Liu, B.
    29. Identification of Posttranslational Modification-Dependent Protein Interactions Using Yeast Surface Displayed Human Proteome Libraries. Methods Mol Biol. 2015; (1319):193-202. Bidlingmaier, S., Su, Y., and Liu, B.
    30. The Development of Potential Antibody-Based Therapies for Multiple Myeloma. Blood Rev. 2015; 2(29):81-91. Sherbenou, D.W., Behrens, C.R. Yang Su, Wolf, J.L., Martin III, T.G., and Liu, B.
    31. Methods for site-specific drug conjugation to antibodies. MAbs. 2014 Jan-Feb; 6(1):46-53. Behrens CR, Liu B. PMID: 24135651; PMCID: PMC3929454.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansAnimals
    32. Enhanced growth inhibition of osteosarcoma by cytotoxic polymerized liposomal nanoparticles targeting the alcam cell surface receptor. Sarcoma. 2012; 2012:126906. Federman N, Chan J, Nagy JO, Landaw EM, McCabe K, Wu AM, Triche T, Kang H, Liu B, Marks JD, Denny CT. PMID: 23024593; PMCID: PMC3447386.
      View in: PubMed   Mentions: 22  
    33. An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors. Mol Imaging Biol. 2012 Jun; 14(3):336-47. McCabe KE, Liu B, Marks JD, Tomlinson JS, Wu H, Wu AM. PMID: 21630083; PMCID: PMC3227780.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    34. Novel human single chain antibody fragments that are rapidly internalizing effectively target epithelioid and sarcomatoid mesotheliomas. Cancer Res. 2011 Apr 01; 71(7):2428-32. Iyer AK, Lan X, Zhu X, Su Y, Feng J, Zhang X, Gao D, Seo Y, Vanbrocklin HF, Broaddus VC, Liu B, He J. PMID: 21447742; PMCID: PMC3071798.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimals
    35. The effect of internalizing human single chain antibody fragment on liposome targeting to epithelioid and sarcomatoid mesothelioma. Biomaterials. 2011 Apr; 32(10):2605-13. Iyer AK, Su Y, Feng J, Lan X, Zhu X, Liu Y, Gao D, Seo Y, Vanbrocklin HF, Courtney Broaddus V, Liu B, He J. PMID: 21255833; PMCID: PMC3040448.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimals
    36. Construction of yeast surface-displayed cDNA libraries. Methods Mol Biol. 2011; 729:199-210. Bidlingmaier S, Liu B. PMID: 21365492; PMCID: PMC3228857.
      View in: PubMed   Mentions: 9     Fields:    Translation:AnimalsCells
    37. Identification of protein/target molecule interactions using yeast surface-displayed cDNA libraries. Methods Mol Biol. 2011; 729:211-23. Bidlingmaier S, Liu B. PMID: 21365493; PMCID: PMC3229213.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    38. Comprehensive analysis of yeast surface displayed cDNA library selection outputs by exon microarray to identify novel protein-ligand interactions. Mol Cell Proteomics. 2011 Mar; 10(3):M110.005116. Bidlingmaier S, Wang Y, Liu Y, Zhang N, Liu B. PMID: 21127146; PMCID: PMC3047160.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    39. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther. 2010 Sep; 18(9):1650-6. Chen Y, Zhu X, Zhang X, Liu B, Huang L. PMID: 20606648; PMCID: PMC2956922.
      View in: PubMed   Mentions: 207     Fields:    Translation:HumansAnimalsCells
    40. Targeting prostate cancer cells in vivo using a rapidly internalizing novel human single chain antibody fragment. J Nucl Med. 2010; 3(51):417-32. He, J., Wang, Y., Feng, J., Zhu, J., Lan, X., Iyer, A.K., Zhang, N., Seo, Y., VanBrocklin, H.F., and Liu, B.
    41. Identification of internalizing human single antibodies targeting brain tumor stem cells. Mol Cancer Ther. 2010; 7(9):2131-41. Zhu, X., Bidlingmaier, S., Hashizume, R., James, C.D., Berger, M.S., and Liu, B.
    42. Development of a highly stable and targetable nanoliposomal formulation of topotecan. J Control Release. 2010 Jan 04; 141(1):13-21. Drummond DC, Noble CO, Guo Z, Hayes ME, Connolly-Ingram C, Gabriel BS, Hann B, Liu B, Park JW, Hong K, Benz CC, Marks JD, Kirpotin DB. PMID: 19686789.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    43. Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma. Cancer Res. 2009 Feb 15; 69(4):1570-7. Bidlingmaier S, He J, Wang Y, An F, Feng J, Barbone D, Gao D, Franc B, Broaddus VC, Liu B. PMID: 19221091; PMCID: PMC2752656.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansAnimalsCells
    44. Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion. J Mol Med. 2009; 5(87):507-14. Conrad, F., Zhu, X., Zhang, X., Chalkley, R.J., Burlingame, A.L., Marks, J.D., and Liu, B.
    45. The utility and limitation of CD133 epitopes in defining tumor stem cell population. J Mol Med. 2008; 9(86):1025-32. Bidlingmaier, S., Zhu, X., and Liu, B.
    46. Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single chain antibodies. Mol Cancer Ther. 2008; 3(7):569-78. An, F., Drummond, D.C., Wilson, S., Kirpotin, D.B., Nishimura, S., Broaddus, C.V. and Liu, B.
    47. Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies. Mol Immunol. 2007 Jul; 44(15):3777-88. Goenaga AL, Zhou Y, Legay C, Bougherara H, Huang L, Liu B, Drummond DC, Kirpotin DB, Auclair C, Marks JD, Poul MA. PMID: 17498801; PMCID: PMC2739904.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    48. Explore Cell Type-Specific Internalizing Antibodies For Targeted siRNA Delivery. Brief Funct Genomic Proteomic. 2007; 2(6):112-9. Liu, B.
    49. Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther. 2007; 10(6):2737-46. Roth, A, Conrad, F., Hayes, M., Drummond, D.C., Kirpotin, D.B., Benz, C.C., Marks, J.D., and Liu, B.
    50. Interrogating yeast surface-displayed human proteome to identify small molecule-binding proteins. Mol Cell Proteomics. 2007; 11(6):2012-20. Bidlingmaier, S and Liu, B.
    51. Prostate cancer targeting recombinant human IgG1s. J Mol Med. 2007; 10(85):1113-23. Liu, B., Conrad, F., Roth, A., Drummond, D.C and Marks, J.D.
    52. Identification of clinically significant tumor antigens by selecting phage antibody library on tumor cells in situ using laser capture microdissection. Mol Cell Proteomics. 2006; 12(5):2364-73. Ruan, W., Sassoon, A., An, F., Simko, J.P., Liu, B.
    53. Construction and application of a yeast surface-displayed human cDNA library to identify post-translational modification-dependent protein-protein interactions. Mol Cell Proteomics. 2006; 3(5):533-40. Bidlingmaier, S. and Liu, B.
    54. Mapping tumor epitope space by direct selection of single chain Fv antibody libraries on prostate cancer cells. Cancer Res. 2004; 2(64):704-710. Liu, B., Conrad, F., Cooperberg, M.R., Kirpotin, D.B., Marks, J.D.
    55. Towards proteome-wide production of monoclonal antibody by phage display. J Mol Biol. 2002; 5(315):1063-1073. Liu, B., Huang, L., Burlingame, A.L., Marks, J.D.
    56. Applying phage antibodies to proteomics: selecting single chain Fv antibodies to antigens blotted on nitrocellulose. Anal Biochem. 2000 Nov 01; 286(1):119-28. Liu B, Marks JD. PMID: 11038282.
      View in: PubMed   Mentions: 12     Fields:    Translation:AnimalsCells
    57. Head-on collision between a DNA replication apparatus and RNA polymerase transcription complex. Science. 1995 Feb 24; 267(5201):1131-7. Liu B, Alberts BM. PMID: 7855590.
      View in: PubMed   Mentions: 100     Fields:    Translation:Cells
    58. Organizational change as human process, not technique. NIDA Res Monogr. 1995; 155:119-31. Diamond MA. PMID: 8594452.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    59. A transcribing RNA polymerase molecule survives DNA replication without aborting its growing RNA chain. Proc Natl Acad Sci U S A. 1994 Oct 25; 91(22):10660-4. Liu B, Wong ML, Alberts B. PMID: 7524099; PMCID: PMC45081.
      View in: PubMed   Mentions: 17     Fields:    Translation:Cells
    60. The DNA replication fork can pass RNA polymerase without displacing the nascent transcript. Nature. 1993 Nov 04; 366(6450):33-9. Liu B, Wong ML, Tinker RL, Geiduschek EP, Alberts BM. PMID: 8232535.
      View in: PubMed   Mentions: 39     Fields:    Translation:Cells
    Bin's Networks
    Concepts (145)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (9)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.